<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079074</url>
  </required_header>
  <id_info>
    <org_study_id>2017YS031</org_study_id>
    <nct_id>NCT05079074</nct_id>
  </id_info>
  <brief_title>Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer</brief_title>
  <acronym>ACTDNA</acronym>
  <official_title>Clinical Application of Circulating Tumor DNA (ctDNA) to Monitor the Molecular Tumor Burden in Patients With Late-stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, observational, multi-center clinical study of circulating tumor DNA&#xD;
      (ctDNA) application in late-stage breast cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to evaluate the feasibility of plasma ctDNA mutation spectrum and clonal&#xD;
      spectrum in guiding late-line treatment and in evaluating the prognosis of late-stage&#xD;
      metastatic breast cancer patients. Meanwhile, this study tries to establish a model of ctDNA&#xD;
      subtyping system to evaluate the molecular load of tumor, to evaluate the curative effect&#xD;
      comprehensively and to detect the disease progression in advance. In addition, the&#xD;
      investigators plan to explore the clonal evolution of ctDNA in patients with progressive&#xD;
      disease (PD), and to monitor the changes of tumor heterogeneity from the molecular level, so&#xD;
      as to provide reference for the analysis of drug sensitivity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From the beginning of the treatment to the end of Cycle 2 (each cycle is 28 days) of treatment.</time_frame>
    <description>The total rate of CR+PR+SD after the completion of two cycles of late-line therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>From the date of recruitment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.</time_frame>
    <description>The survival time between the beginning of treatment to death or the progression.</description>
  </primary_outcome>
  <other_outcome>
    <measure>ctDNA change index</measure>
    <time_frame>From the date of recruitment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.</time_frame>
    <description>The dynamic change of the frequency spectrum of ctDNA mutation in plasma.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">223</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Circulating Tumor DNA</condition>
  <condition>Gene Abnormality</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Control group included patients without ctDNA abnormality and patients without druggable ctDNA abnormality.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <description>Case group included patients with druggable ctDNA abnormality.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Druggable ctDNA alteration-guided therapy</intervention_name>
    <description>Case group</description>
    <arm_group_label>Case group</arm_group_label>
    <other_name>PARP inhibitor</other_name>
    <other_name>EGFR inhibitor</other_name>
    <other_name>CDK4/6 inhibitor</other_name>
    <other_name>AR antagonists</other_name>
    <other_name>anti-VEGFR</other_name>
    <other_name>anti-FGFR</other_name>
    <other_name>Fulvestrant</other_name>
    <other_name>ADC drugs</other_name>
    <other_name>PI3K inhibitor</other_name>
    <other_name>Anti-HER2 treatment</other_name>
    <other_name>HDAC inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physician chosen treatment</intervention_name>
    <description>Control group</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood lymphocytes (PBL) and plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This cohort study recruited consecutive patients with recent progression of metastatic TNBC&#xD;
        after multiple lines of chemotherapy or of HR+ or HER2+ metastatic breast cancer after&#xD;
        multiple lines of endocrine or targeted therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recent progression of TNBC after multiple lines of chemotherapy or of HR+ or HER2+ MBC&#xD;
             after multiple lines of endocrine or targeted therapy;&#xD;
&#xD;
          -  No available recommendation for the next treatment regimen;&#xD;
&#xD;
          -  An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;&#xD;
&#xD;
          -  An updated, available pathological HR/HER2 status for metastasis;&#xD;
&#xD;
          -  According to RECIST 1.1 standard, there should be at least one measurable target&#xD;
             lesion;&#xD;
&#xD;
          -  The expected survival time is &gt; 3 months;&#xD;
&#xD;
          -  Those aged 18-70 years old;&#xD;
&#xD;
          -  Liver and kidney function and blood routine test meet the following conditions:&#xD;
             Neutrophil &gt; 2.0g/l, Hb &gt; 9g / L, PLT &gt; 100g / L; ALT and AST &lt; 2.5ULN; TBIL &lt; 1.5ULN;&#xD;
             Cr &lt; 1.0ULN&#xD;
&#xD;
          -  Signing informed consent;&#xD;
&#xD;
          -  Those willing to accept polygenic testing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with multiple primary tumors;&#xD;
&#xD;
          -  Those who are unable to obtain blood samples;&#xD;
&#xD;
          -  Those with a history of immunodeficiency or organ transplantation;&#xD;
&#xD;
          -  Those with abnormal cardiac function or previous history of myocardial infarction or&#xD;
             serious arrhythmia;&#xD;
&#xD;
          -  The researchers think it is not suitable to participate in this experiment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quchang Ouyang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013 Aug;10(8):472-84. doi: 10.1038/nrclinonc.2013.110. Epub 2013 Jul 9. Review.</citation>
    <PMID>23836314</PMID>
  </reference>
  <reference>
    <citation>Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013 Mar 28;368(13):1199-209. doi: 10.1056/NEJMoa1213261. Epub 2013 Mar 13.</citation>
    <PMID>23484797</PMID>
  </reference>
  <reference>
    <citation>Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021.</citation>
    <PMID>26311728</PMID>
  </reference>
  <reference>
    <citation>Murtaza M, Dawson SJ, Pogrebniak K, Rueda OM, Provenzano E, Grant J, Chin SF, Tsui DWY, Marass F, Gale D, Ali HR, Shah P, Contente-Cuomo T, Farahani H, Shumansky K, Kingsbury Z, Humphray S, Bentley D, Shah SP, Wallis M, Rosenfeld N, Caldas C. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun. 2015 Nov 4;6:8760. doi: 10.1038/ncomms9760.</citation>
    <PMID>26530965</PMID>
  </reference>
  <reference>
    <citation>Swanton C, Govindan R. Clinical Implications of Genomic Discoveries in Lung Cancer. N Engl J Med. 2016 May 12;374(19):1864-73. doi: 10.1056/NEJMra1504688. Review.</citation>
    <PMID>27168435</PMID>
  </reference>
  <reference>
    <citation>Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, Aas T, Alexandrov LB, Larsimont D, Davies H, Li Y, Ju YS, Ramakrishna M, Haugland HK, Lilleng PK, Nik-Zainal S, McLaren S, Butler A, Martin S, Glodzik D, Menzies A, Raine K, Hinton J, Jones D, Mudie LJ, Jiang B, Vincent D, Greene-Colozzi A, Adnet PY, Fatima A, Maetens M, Ignatiadis M, Stratton MR, Sotiriou C, Richardson AL, Lønning PE, Wedge DC, Campbell PJ. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015 Jul;21(7):751-9. doi: 10.1038/nm.3886. Epub 2015 Jun 22.</citation>
    <PMID>26099045</PMID>
  </reference>
  <results_reference>
    <citation>Hu ZY, Xie N, Tian C, Yang X, Liu L, Li J, Xiao H, Wu H, Lu J, Gao J, Hu X, Cao M, Shui Z, Xiao M, Tang Y, He Q, Chang L, Xia X, Yi X, Liao Q, Ouyang Q. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance. EBioMedicine. 2018 Jun;32:111-118. doi: 10.1016/j.ebiom.2018.05.015. Epub 2018 May 26.</citation>
    <PMID>29807833</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT05079074/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

